Category: obesity
-
Viking obesity drug to rival Eli Lilly’s: report (NASDAQ:VKTX)
•
Carolina Rhoda/iStock via Getty Images Eli Lilly (NYSE:LLYPopular obesity treatment Zepbound could face direct competition from Viking TherapeuticsNASDAQ:VKTX), with the latter expected to launch its flagship weight loss product VK2735 within the next few years, according to data analytics firm GlobalData. He said this week. The prediction comes after the…
-
Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss
•
New data shows significant loss of fat mass while maintaining lean mass NATICK, Mass.–(BUSINESS WIRE)–Allurion Technologies, Inc. today announced… (NYSE: ALUR), a company dedicated to eliminating obesity, announced three scientific presentations at the 31st European Congress on Obesity (ECO) in Venice, Italy. , on May 12-15, 2024. The presentations include…
-
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
•
Weight loss translates into profits for investors. Just look at Eli Lilly And Novo Nordisk. Both stocks have risen dramatically thanks in large part to their obesity drugs, with Lilly’s stock more than quadrupling and Novo’s stock more than tripling over the past three years. while, Pfizer’s (NYSE: PFE) Fortunes…